top | item 24136226

‘AeroNabs’ Promise Powerful, Inhalable Protection Against Covid-19

21 points| jacquesm | 5 years ago |ucsf.edu

11 comments

order
[+] Animats|5 years ago|reply
Competing Interest Statement

"M. Schoof, B. Faust, R. Saunders, N. Hoppe, P. Walter, and A. Manglik are inventors on a provisional patent describing anti-Spike nanobodies described in this manuscript."

PR for this has reached every outlet from USA Today to sci.electronics.design on Usenet. However, there seems to be zero commentary on it from serious medical sites or journals.

[+] dharmab|5 years ago|reply
"Promise" is maybe too strong a word for something that has only been shown to neutralize the virus in liquid form in in vitro cell culture so far.
[+] sp332|5 years ago|reply
School press releases are always like this for alumni projects.
[+] exabrial|5 years ago|reply
Long way to verifying the safety, given the particle size, but that's a fairly novel mechanism of action from my limited knowledge.
[+] shahar2k|5 years ago|reply
A friend (PhD researcher) introduced me to nanobodies and the science around them a few years back, it's pretty fascinating and cool to see more and more practical applications.
[+] credit_guy|5 years ago|reply
> As the world awaits vaccines to bring the COVID-19 pandemic under control, UC San Francisco scientists have devised a novel approach to halting the spread of SARS-CoV-2, the virus that causes the disease.

Not clear at all how this thing can be ready for use before vaccines become available. This is a long way before Phase 1 clinical trials, while quite a few vaccines are well into their Phase 3 trials.

[+] LeoNatan25|5 years ago|reply
Vaccine efficacy is not yet proven. Even if highly effective, vaccines will take years to circulate the world. Something like this, much easier to produce, supposedly, can fill that vaccine gap.
[+] DrAwdeOccarim|5 years ago|reply
This is super cool, but unfortunately a little too late to the game. We will likely have a vaccine by Feb next year. To scale-up a protein antibody, run trials, and get approval for such a novel idea--plus you would need the device to be either CE or approved already because that would take a whole lot longer if not--will take best case 1 year. Doesn't mean they shouldn't find an industry partner to go for it, but I doubt anyone would pick it up without government backstopping and right now the focus is on vaccine and mAb scale-up.
[+] sjnu|5 years ago|reply
This sounds like a great way to solve the “vaccines don’t give recurring income” problem.